TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07491458: A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Sponsor: Rivus Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,263,800

Rescue Site Savings

+$1,499,400

Unlock Full NCT07491458 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07491458 Rescue Dossier →